Clinical Trial Search

Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants

Primary: Re-infection With S. Aureus — 10; 11; 0; 0 participants with S. aureus re-infection — p=0.356

Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score

Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035

Primary: Medically Attended Skin and Soft Tissue Infections (MA-SSI) — 20.9; 17 percentage of partipants

Primary: Number of Index Patients Eradicated of S. Aureus Carriage - 1 Month After Performing Decolonization Measures — 39; 35 Participants — p=1.00

Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants

Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants

Primary: Carrier Rate for Staphylococcus Aureus — 20.8 percentage of subjects

Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) Following Multiple Doses of Intravenous AP-Sa02. — 17; 10; 6; 2 number of…

Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants

Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants

Primary: Assessment of Safety Through Clinical Examinations, Clinical Laboratory Results, Self-reported Diary Reactogenicity Data and Adverse Event Reports — 37; 40; 28; 36 events

Primary: Number of Participants Eradicated of S. Aureus Carriage - 1 Month After Intervention — 24; 35; 35; 34 Participants

Primary: Apparent Eradication of Nasal Carriage of SA — 9 participants

Primary: Surgical Site Infections Occurring Within 12 Months of Surgical Procedure — 0; 5 participants

Primary: Rates of Staphylococcus Aureus Acquisition: Percentage of Short Stay Participants Who Acquired MRSA or MSSA (or Both) During the Study Period — 17; 8 Participants

Primary: Number of Participants Who Experienced Dose-limiting Toxicities — 0; 0; 0; 0 participants

Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…

Primary: Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit — 132; 136; 57; 62 Participants

Primary: Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days — 18; 7 Participants

Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…

Primary: MRSA Transmission — 0.20; 0.02; 0.11; 0.01 Proportion of swabs positive for MRSA

Primary: Efficacy Endpoint: All-Cause Mortality by Day 28 — 1; 2; 2; 0 Participants

Primary: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to Adverse Events (AEs) — 1 incidence

Primary: Incidence of Adverse Events [Safety and Tolerability] — 48; 30; 64; 40 Participants

Primary: Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture — 2; 3 Participants

Primary: Change in S. Aureus Log CFU/mL From Baseline to Pre-surgery — -2.842; -0.469 log10 (CFU/mL)

Primary: Recurrent Infection — 1; 3; 1 participants

Primary: Number of Participants With Solicited Adverse Events (AEs) During Days 1-7 — 2; 1; 17; 4 participants